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Abstract: Natalizumab, a new disease-modifying therapy for relapsing remitting multiple 
sclerosis (RRMS), is a humanized monoclonal antibody which binds to α4β1-integrin. In a Phase 
3 trial, 2 years of natalizumab monotherapy reduced the mean annualized relapse rate (ARR) 
by 68% compared with placebo (p < 0.001) and the risk of sustained disability progression was 
reduced by 42% in the natalizumab group (hazard ratio [HR] 0.58; 95% conﬁ  dence interval 
[CI] 0.43–0.77; p < 0.001). Natalizumab decreased the mean number of new or enlarging 
T2-hyperintense lesions by 83% over 2 years and the mean number of Gd+ lesions by 92% 
at 2 years (both p < 0.001). In another Phase 3 trial, natalizumab with interferon (IFN) β-1a 
reduced the mean ARR by 55% at 2 years compared with IFNβ-1a alone (p < 0.001) and risk of 
sustained disability progression was reduced by 24% (HR 0.76; 95% CI 0.61–0.96; p = 0.02). 
Six percent of patients developed persistent antinatalizumab antibodies with loss of efﬁ  cacy. 
The risk of developing progressive multifocal leukoencephalopathy (PML) is been estimated 
at 1:1000 over 18 months; the longer term risk for PML is uncertain. The beneﬁ  ts and risks 
of natalizumab support its use as monotherapy for RRMS with high disease activity despite 
treatment with IFNβ, and for patients with rapidly evolving severe RRMS. 
Keywords: natalizumab, Tysabri, multiple sclerosis, α4-integrin antagonist, selective adhesion 
molecule (SAM) inhibitor, disease-modifying therapy
Introduction
Multiple sclerosis (MS) is a chronic disabling autoimmune neurological disease 
affecting approximately 2.5 million people worldwide. The initial presentation in most 
patients (85%) is relapsing-remitting MS (RRMS) with relapses and remissions due to 
self-limiting plaques of inﬂ  ammatory demyelination disseminated in time and place 
in the central nervous system (CNS). Subsequently, chronic noninﬂ  ammatory loss of 
CNS axons gives rise to progressive disability (secondary progressive MS [SPMS]). 
Approximately 10%–15% of MS patients have progressive disability from the outset 
(primary progressive MS [PPMS]). (MSIF 2006; NMSS 2006). Clinical relapses in MS 
are due to acute inﬂ  ammatory CNS demyelinating lesions causing white matter plaques. 
After a variable period (usually 10–15 years) of recurrent relapses with accumulating 
residual disability, the patient enters a course of inexorable slowly progressive disability 
(SPMS) due to secondary axonal degeneration. The pathogenesis is best understood 
as a complex interaction between genetic predisposition and environmental stimuli. 
Autoimmune reaction against different components of the CNS, particularly myelin 
structures, is thought to play an important role in the initiation of the inﬂ  ammatory 
process. The transmigration of cells into the target tissue is regulated by chemotactic 
cytokines and adhesion molecule expression at the blood-brain barrier. The primary 
goals of MS therapy are to reduce relapses, reduce accumulating residual disability, 
and to prevent or delay the onset of progressive disability. Although the cause of Therapeutics and Clinical Risk Management 2007:3(2) 260
Hutchinson
MS is unknown, effective therapies are aimed at reducing 
the inﬂ  ammatory disease process; natalizumab is the ﬁ  rst 
targeted therapy which blocks an essential mechanism 
for lymphocyte entry to the CNS and thus prevents acute 
demyelinating relapses. 
While some treatments for MS provide only symptom 
relief, disease-modifying therapies (DMTs) are administered 
with the goal of altering the course of the disease. Available 
DMTs include interferon beta-1a (IFNβ-1a) (Avonex®, 
Biogen Idec, Cambridge, MA, USA; Rebif®, Serono, 
Rockland, MA, USA), IFNβ-1b (Betaseron®, Berlex 
Laboratories, Montville, NJ, USA), glatiramer acetate 
(GA) (Copaxone®, TEVA Neuroscience, Kansas City, MO, 
USA), and mitoxantrone (MITO) (Novantrone®, Serono, 
Rockland, MA, USA). First-line DMT for MS is one of 
the IFNs or GA, which are generally well tolerated but 
only modestly effective (IFNB 1993; Johnson et al 1995; 
Jacobs et al 1996; PRISMS 1998; 2001); because of toxicity 
concerns, mitoxantrone is used more selectively in patients 
with very active disease characterized by frequent relapses 
and accumulating disability (Ghalie et al 2002; Avasarala 
et al 2003; Cohen and Mikol 2004). Since approximately 
two thirds of patients treated with IFNs or GA relapse and 
eventually experience disease progression, there is a clear 
unmet medical need for more effective agents (IFNB 1993; 
Johnson et al 1995; Jacobs et al 1996; PRISMS 1998; 2001). 
Detailed analysis of therapeutic studies of current ﬁ  rst-line 
DMT therapy in MS may be found in a number of reviews 
(Galetta et al 2002; Filippini et al 2003; Munari et al 2003; 
Rice at al 2006).
Natalizumab (Tysabri®, Biogen Idec, Cambridge, MA, 
USA) is a new DMT licensed in 2006 in the EU and in the 
US for the treatment of RRMS. The main focus of this article 
is to review evidence from the Phase 1, 2, and 3 clinical 
trials of natalizumab that led to its approval. Advantages 
of natalizumab in treating MS include a unique mechanism 
of action, a new level of clinical efﬁ  cacy greater than that of 
other available DMTs, good tolerability, and a convenient 
monthly dosing regimen. 
Methods
A search of articles indexed in the PubMed database 
(January 1966–February 2006) and the Cochrane Library 
was conducted using the query terms natalizumab, Tysabri, 
Antegren, multiple sclerosis, and MS. The results of clinical 
trials described in the published literature, as well as data 
provided by Biogen Idec, were used in this review.
Mechanism of action
Natalizumab is the ﬁ  rst in a class of DMTs known as selective 
adhesion molecule (SAM) inhibitors (Léger et al 1997) and 
acts by preventing the speciﬁ  c inﬂ  ammatory events leading 
to the development of MS lesions.
Endothelial cells on the lumen of blood vessels express 
vascular cell adhesion molecule-1 (VCAM-1) at sites of 
active MS lesions (Osborn et al 1989; Carlos et al 1990). 
VCAM-1 is bound by α4β1-integrin (also known as very late 
antigen-4), an adhesion molecule found at high levels on the 
surface of all leukocytes except neutrophils (Elices et al 1990; 
Lobb and Hemler 1994). The interaction between VCAM-1 
and α4β1-integrin is required for leukocyte adhesion, ﬁ  rm 
attachment, and transmigration across the blood-brain 
barrier into the CNS (Damle and Aruffo 1991; Burkly et al 
1991; Lobb and Hemler 1994). Natalizumab, a recombinant, 
humanized antibody, binds to α4β1-integrin and blocks its 
interaction with VCAM-1. As a result, leukocyte migration 
into brain tissue is inhibited, reducing inﬂ  ammation and 
preventing the formation of lesions (Tubridy et al 1999; 
Rudick and Sandrock 2004). Natalizumab may also inhibit 
ongoing CNS inﬂ  ammation, mediated by leukocytes already 
present in the CNS, by interrupting the interactions between 
α4-integrin-expressing leukocytes and extracellular matrix 
proteins such as ﬁ  bronectin and osteopontin (Lobb and 
Hemler 1994; Bayless et al 1998).
Natalizumab binds rapidly and with high afﬁ  nity to α4-
integrin. Maximal binding (≥80% saturation), measured in 
vitro on isolated lymphocyte membranes, occurred 24 hours 
after intravenous (IV) doses of natalizumab 1 mg/kg to 6 
mg/kg; saturation persisted for 1 to 6 weeks, with longer 
residence times achieved at higher dose levels (Rudick and 
Sandrock 2004; Biogen Idec Data on File). MS patients 
treated with natalizumab 3 mg/kg or 6 mg/kg IV achieved 
approximately 80% and 90% mean saturation of α4-integrin, 
respectively (Miller et al 2003; Biogen Idec Data on File). 
Weight-based dosing data from Phase 2 trials suggested 
that a single ﬁ  xed dose of 300 mg would maintain maximal 
α4-integrin saturation for over 4 weeks (Bennett et al 
2002; Rudick and Sandrock 2004). The dosage of 300 mg, 
administered every 4 weeks in Phase 3 trials of natalizumab, 
saturated α4-integrin to a mean level of ≥70% (Biogen Idec 
Data on File).
Pharmacokinetics
The pharmacokinetics of natalizumab (0.03 mg/kg to 
6 mg/kg) was examined in four Phase 1 trials: one in Therapeutics and Clinical Risk Management 2007:3(2) 261
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healthy volunteers and three in patients with MS (Sheremata 
et al 1999; Rudick and Sandrock 2004; Vollmer et al 2004; 
Biogen Idec Data on File). Serum natalizumab concentrations 
quickly dropped below the detection limits with 0.03 mg/kg 
or 0.1 mg/kg IV doses, but were measurable for 1 week with 
the 0.3 mg/kg IV dose and for 3 to 8 weeks with the 1 mg/kg 
and 3 mg/kg IV doses (Sheremata et al 1999). Higher doses 
of natalizumab resulted in longer mean half-lives and slower 
mean total body clearance, despite the use of weight-based 
dosing (Sheremata et al 1999).
Analysis of pharmacokinetic data from Phase 2 trials and 
population modeling indicated that natalizumab clearance 
was only weakly correlated with body weight (over the range 
of 40 kg to 100 kg), but that natalizumab exposure (area under 
the plasma concentration-time curve and maximum plasma 
concentration), increased in proportion to weight despite 
the use of weight-based dosing (Bennett et al 2002; Rudick 
and Sandrock 2004; Biogen Idec Data on File). However, 
the effect of patient weight on natalizumab clearance and 
exposure was within the typical inter-patient range and was 
not considered clinically relevant. The 300 mg ﬁ  xed dose 
selected to achieve maximum α4-integrin saturation was 
expected to produce acceptable pharmacokinetics in Phase 3 
trials (Table 1). The clearance of natalizumab allows dosing 
once every 4 weeks, during a clinic visit lasting 2 hours, while 
most other DMTs must be self-injected daily, on alternate 
days, or weekly. 
Coadministration of other drugs does not appear to 
significantly affect natalizumab pharmacokinetics. In a 
Phase 1 trial, 38 patients with RRMS who had been treated 
with a stable weekly dose of IFNβ-1a 30 µg intramuscularly 
(IM) for at least 3 months prior to enrollment received a 
single IV dose of natalizumab 3 mg/kg or 6 mg/kg (Vollmer 
et al 2004). Natalizumab serum levels were slightly elevated 
when given in addition to IFNβ-1a. Natalizumab treatment 
had no signiﬁ  cant effect on the pharmacokinetics of IFNβ-
1a (Vollmer et al 2004). A Phase 2 trial investigated the use 
of natalizumab in combination with GA and the potential 
effects of each drug on pharmacokinetics (Table 2; see also 
below under “Phase 2b trial”) (Goodman et al 2005); however, 
results have not yet been published.
Efﬁ  cacy data from clinical studies
As described in this section, the efﬁ  cacy of natalizumab in 
treating MS has been evaluated in a number of randomized, 
controlled clinical studies (Tubridy et al 1999; Miller et al 
2003; O’Connor et al 2004; Goodman et al 2005; Polman 
et al 2006; Rudick, Stuart, et al 2006). To date, no study has 
directly compared monotherapy with natalizumab against 
monotherapy with a different DMT. Therefore, comparisons 
of natalizumab and other DMTs must consider differences 
in patient characteristics, comedication, study design, and 
choice of endpoints. Clinical trials recruit different types of 
patients in terms of MS diagnosis (eg, RRMS and secondary 
progressive MS [SPMS]), previous treatment history (none, 
recent, IFNβ-1a, and GA), and duration of disease.
Phase 2 trials
The Phase 2 trials of natalizumab are summarized in Table 2. 
To assess the efﬁ  cacy of natalizumab in the short-term 
control of brain lesion formation, a randomized, double-
blind, placebo-controlled, multicenter trial was conducted 
in patients with RRMS or SPMS (Tubridy et al 1999). 
Patients received two IV infusions of natalizumab 3 mg/kg 
(n = 37) or placebo (n = 35), administered at weeks 0 and 4, 
and were followed through week 24. Between weeks 1 and 
12, natalizumab reduced the mean number of new active 
lesions per patient by half compared with placebo (1.8 vs 3.6, 
respectively; p = 0.042). Patients treated with natalizumab 
also developed fewer new gadolinium-enhancing (Gd+) 
lesions, which are associated with breakdown of the blood-
brain barrier, than patients receiving placebo (1.6 vs 3.3 mean 
lesions per patient, respectively; p = 0.017) during weeks 
1 to 12. During weeks 12 to 24, there were no statistically 
signiﬁ  cant differences between treatment groups in the mean 
cumulative number of new Gd+ lesions or in the proportion 
of scans without new Gd+ lesions. It also was noted that, 
during weeks 12 to 24, patients who had been treated with 
natalizumab had a higher relapse rate than those who had 
received placebo. This difference was attributed to an unusual 
decrease in relapses in the placebo group, rather than to an 
increase in the natalizumab group. No other studies have 
Table 1 Pharmacokinetic parameters after repeated doses of 
natalizumab 300 mg in patients with multiple sclerosis (Tysabri 
PI 2006)
Parameter  Mean ± SD
Cmax, µg/mL  110 ± 52
Css, µg/mL  23 to 29
CL, mL/h  16 ± 5
Vd, L  5.7 ± 1.9
t1/2, d  11 ± 4
Abbreviations: CL, clearance; Cmax, maximum plasma concentration; Css, mean 
steady-state concentration; SD, standard deviation; t1/2, elimination half-life; Vd, 
volume of distribution.Therapeutics and Clinical Risk Management 2007:3(2) 262
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found an increase in disease activity beyond the untreated 
state after stopping natalizumab treatment (Miller et al 
2003; O’Connor et al 2006). Tubridy and colleagues (1999) 
concluded that natalizumab was superior to placebo in 
reducing the formation of brain lesions, but that the duration 
of the study was too short to detect possible differences in 
clinical outcomes.
A randomized, double-blind, placebo-controlled, 
multicenter trial assessed the effects of IV natalizumab 
3 mg/kg (n = 68), natalizumab 6 mg/kg (n = 74), or placebo 
(n = 71) administered every 4 weeks for 6 months to patients 
with RRMS or SPMS (Miller et al 2003). All patients were 
followed for an additional 6 months. This study had a longer 
treatment period and enrolled more patients than the study 
by Tubridy and colleagues (1999). As with the previous 
study, the primary endpoints were evaluated by magnetic 
resonance imaging (MRI) measurements of brain lesions 
(Miller et al 2003). Secondary and tertiary endpoints were 
clinical measures such as relapses, disability progression, 
and patient well-being. During the 6-month treatment period, 
MRI data showed that natalizumab dramatically reduced the 
mean number of new Gd+ lesions compared with placebo 
(9.6 lesions per patient in the placebo group, 0.7 in the 
natalizumab 3 mg/kg group, and 1.1 in the natalizumab 6 mg/
kg group; p < 0.001 for either natalizumab dose vs placebo). 
There was no statistically signiﬁ  cant difference between the 
two natalizumab dose groups. Natalizumab also markedly 
reduced the mean number of persistent Gd+ lesions, the 
mean total volume of Gd+ lesions, and the mean number of 
new active lesions (p ≤ 0.01 vs placebo for all comparisons). 
Clinical results showed that natalizumab reduced the number 
of patients who experienced a relapse by approximately half 
compared with placebo during the 6-month treatment period 
(19% for either active treatment group vs 38% in the placebo 
group; p = 0.02 for both comparisons). No statistically 
signiﬁ  cant changes in disability, as measured by expanded 
disability status scale (EDSS), were observed in any group. A 
patient-assessed visual analogue scale showed improvements 
in the natalizumab treatment groups and a small worsening 
in the placebo group (p ≤ 0.04, natalizumab vs placebo). 
The use of corticosteroids to ameliorate relapses was also 
signiﬁ  cantly reduced in the natalizumab groups compared 
with placebo (p ≤ 0.001), suggesting that relapse symptoms 
for patients treated with natalizumab were less intense than 
for patients receiving placebo. The main conclusions of this 
study were that natalizumab dramatically reduced lesion 
formation and relapses, and that longer-term studies were 
needed to assess the effect of natalizumab on progression 
of disability (Miller et al 2003).
A subgroup analysis of the same study examined 
whether natalizumab could reduce the conversion of Gd+ 
lesions, which are associated with ongoing inﬂ  ammation 
and demyelination, to more permanent T1-hypointense 
lesions (Miller et al 2003; Dalton et al 2004). Patients were 
included in the subgroup analysis if they had one or more 
new Gd+ lesions during months 0 to 6 of treatment and had 
at least 6 months of follow-up data (Dalton et al 2004). To 
improve statistical power, data from both natalizumab dose 
groups were pooled (n = 40) for analysis against placebo 
(n = 38) group data. At month 12, Gd+ lesions converted to 
T1-hypointense lesions in 26% of patients in the natalizumab 
group compared with 68% of those in the placebo group 
(p < 0.01) (Dalton et al 2004). 
The clinical efﬁ  cacy of natalizumab in treating acute MS 
relapses was investigated in a randomized, double-blind, 
placebo-controlled, multicenter trial of 180 patients with 
RRMS or SPMS (O’Connor et al 2004). This study assessed 
the effects of a single IV dose of natalizumab 1 mg/kg 
(n = 57), natalizumab 3 mg/kg (n = 60), or placebo (n = 63), 
administered 1 to 4 days after the start of an acute relapse, 
on clinical outcomes over 14 weeks. Patients did not receive 
corticosteroids, which typically would be prescribed in cases 
of relapse. No statistically signiﬁ  cant differences in clinical 
endpoints were observed with natalizumab versus placebo. 
While post-hoc analysis revealed less of an increase in the 
mean volume of Gd+ lesions in the natalizumab groups 
compared with the placebo group at week 1 (p = 0.021 for 
combined natalizumab groups vs placebo) and at week 3 
(p = 0.024 for combined natalizumab groups vs placebo), no 
differences were seen at week 14. These results suggested 
that natalizumab would not be appropriate for acute relapses, 
but rather showed more promise as preventative therapy 
(O’Connor et al 2004).
Phase 2b trial
Glatiramer acetate is a DMT used for the treatment of 
relapsing-remitting MS. Because the mechanism of action 
of GA may depend on Th2 lymphocytes entering the CNS 
(Aharoni et al 2000), a process blocked by natalizumab, 
concern arose about possible interference between the two 
therapies. To investigate the consequences of combining 
GA and natalizumab therapies, the GLANCE (Glatiramer 
Acetate and Natalizumab Combination Evaluation) study was 
conducted (Table 2) (Goodman et al 2005). This randomized, Therapeutics and Clinical Risk Management 2007:3(2) 264
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double-blind, placebo-controlled, multicenter safety trial 
enrolled 110 patients with RRMS who had been treated with 
GA (≥20 mg/day) for at least 1 year and who had experienced 
at least one relapse during this time. All patients continued to 
receive GA and also received either placebo or natalizumab 
300 mg, administered by IV infusion every 4 weeks for 
up to 20 weeks. The primary endpoint was the rate of new 
active lesions detected by brain MRI scans. The study has 
been completed, but the results are not yet available in the 
peer-reviewed literature.
Phase 3 trials
Two randomized, double-blind, placebo-controlled, multicenter, 
Phase 3 trials of natalizumab in patients with relapsing MS 
have been conducted: AFFIRM (Natalizumab Safety and 
Efficacy in Relapsing-Remitting MS) and SENTINEL 
(Safety and Efﬁ  cacy of Natalizumab in Combination with 
Avonex® [IFNβ-1a] in Patients with Relapsing-Remitting 
MS).
The AFFIRM study evaluated the long-term efﬁ  cacy 
and safety of ﬁ  xed-dose natalizumab 300 mg monotherapy 
(n = 627) versus placebo (n = 315), each administered by IV 
infusion every 4 weeks, in patients with RRMS (Polman et al 
2006). Inclusion criteria required the patients to be aged 18 to 
50 years, have MRI lesions consistent with MS, EDSS score 
of 0.0 to 5.0, and at least one relapse within the previous 12 
months. Patients who experienced a relapse within 50 days 
before the ﬁ  rst dose of study medication were excluded. 
The primary endpoints were the rate of clinical relapses at 
1 year and the rate of sustained progression of disability at 
2 years. Disability progression was deﬁ  ned as a ≥1.0-point 
increase in EDSS score from a baseline EDSS score ≥1.0 (or 
a ≥1.5-point increase in patients with a baseline EDSS score 
of 0) that was sustained for 12 weeks. At 1 year and over 2 
years, natalizumab reduced the mean annualized relapse rate 
by 68% compared with placebo (p < 0.001). Over 2 years, 
the risk of sustained disability progression was reduced by 
42% in the natalizumab group compared with the placebo 
group (hazard ratio [HR] 0.58; 95% conﬁ  dence interval 
[CI] 0.43–0.77; p < 0.001). Natalizumab decreased the 
mean number of new or enlarging T2-hyperintense lesions 
by 83% over 2 years and the mean number of Gd+ lesions 
by 92% at 2 years, compared with placebo (both p < 0.001) 
(Polman et al 2006). Two-year data from AFFIRM are 
summarized in Table 3. Uniquely among studies of DMTs 
in patients with relapsing MS, treatment with natalizumab 
signiﬁ  cantly improved quality of life from baseline to 2 
years as compared with placebo on the mental and physical 
scales of the SF-36 (Ware and Sherbourne 1992; Rudick, 
Hutchinson, et al 2006).
The SENTINEL study evaluated the long-term efﬁ  cacy 
and safety of natalizumab (same regimen as described for 
AFFIRM) when added to the standard regimen of IM IFNβ-
1a (n = 589), compared with IM IFNβ-1a alone (n = 582), 
in patients with RRMS who had experienced breakthrough 
disease while on IFNβ-1a therapy in the prior 12 months 
(Rudick, Stuart, et al 2006). To participate in SENTINEL, 
patients had to be 18 to 55 years of age, have MRI lesions 
consistent with MS, have an EDSS score of 0.0 to 5.0, and 
have at least one relapse within the previous 12 months, 
but not within 50 days before randomization. The primary 
endpoints were identical to those of AFFIRM. Natalizumab/
IFNβ-1a reduced the mean annualized relapse rate by 
54% at 1 year and 55% at 2 years compared with IFNβ-1a 
alone (both p < 0.001). Over 2 years, the risk of sustained 
disability progression, as deﬁ  ned in AFFIRM, was reduced 
by 24% in patients receiving combination therapy compared 
with monotherapy (HR 0.76; 95% CI 0.61–0.96; p = 0.02) 
(Table 3). In addition, natalizumab/IFNβ-1a decreased 
the mean number of new or enlarging T2-hyperintense 
lesions by 83% over 2 years and the mean number of Gd+ 
lesions by 89% at 2 years, compared with IFNβ-1a alone 
(both p < 0.001) (Rudick, Stuart, et al 2006). Treatment 
with natalizumab/IFNβ-1a resulted in better quality of life 
than treatment with alone IFNβ-1a, as measured with the 
SF-36; however, the difference was signiﬁ  cant only for 
the physical scale (Ware and Sherbourne 1992; Rudick, 
Hutchinson, et al 2006).
Adverse effects of natalizumab 
from clinical studies 
Safety and tolerability of natalizumab were evaluated during 
all Phase 1, 2, and 3 trials (Sheremata et al 1999; Tubridy 
et al 1999; Miller et al 2003; O’Connor et al 2004; Vollmer et al 
2004; Polman et al 2006; Rudick, Stuart, and Calabresi 2006; 
Biogen Idec Data on File). Natalizumab was well tolerated 
in Phase 1 trials when administered alone (Sheremata et al 
1999; Rudick and Sandrock 2004; Biogen Idec Data on File) 
or in combination with IM IFNβ-1a(Vollmer et al 2004). In 
all Phase 2 trials, natalizumab was well tolerated and adverse 
events (AEs) were similar among patients receiving either 
natalizumab or placebo (Tubridy et al 1999; Miller et al 2003; 
O’Connor et al 2004). Miller and colleagues (2003) reported 
that levels of lymphocytes, monocytes, and eosinophils, Therapeutics and Clinical Risk Management 2007:3(2) 265
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which express α4β1-integrin, were somewhat elevated during 
natalizumab treatment, but that mean levels remained within 
the normal range. The level of neutrophils, which do not 
express α4β1-integrin, was unaffected. One patient in each 
group (3/213), including the placebo group, developed an 
illness resembling serum sickness, and one patient in the 
3 mg/kg group developed urticaria and bronchospasm that 
were reversed with antihistamines and corticosteroids (Miller 
et al 2003).
Analyses of 2-year safety data from the Phase 3 trials 
have recently been completed and support the excellent 
tolerability profile of natalizumab (Polman et al 2006; 
Rudick, Stuart, et al 2006; Yousry et al 2006). Patient 
withdrawal rates due to AEs were comparable in the different 
arms of the Phase 3 trials, suggesting that natalizumab was 
similarly well tolerated when compared with placebo or 
IFNβ-1a (Polman et al 2006; Rudick, Stuart, et al 2006). In 
AFFIRM, AE rates were not signiﬁ  cantly different between 
the natalizumab and placebo groups, except for fatigue (27% 
vs 21%, respectively) and allergic reactions (9% vs 4%) (both 
p < 0.05). In SENTINEL, combination therapy was 
associated with a somewhat higher incidence of anxiety 
(12% vs 8% in patients receiving IFNβ-1a alone), pharyngitis 
(7% vs 4%), sinus congestion (6% vs 3%), and peripheral 
edema (5% vs 1%) (all p ≤ 0.05) (Rudick, Stuart, et al 2006). 
In both AFFIRM and SENTINEL, infections and serious 
AEs occurred at a low and comparable incidence between 
treatment groups, except that MS relapses were signiﬁ  cantly 
reduced among patients receiving natalizumab (Polman et al 
2006; Rudick, Stuart, et al 2006).
Two cases of progressive multifocal leukoencephalopathy 
(PML), a rare brain disorder; were diagnosed in patients 
with MS who received natalizumab, in combination with 
IFNβ-1a, in the SENTINEL study (Kleinschmidt-DeMasters 
and Tyler 2005; Langer-Gould et al 2005). A third case of 
PML, previously diagnosed as astrocytoma, was later identiﬁ  ed 
post-mortem in a patient with Crohn’s disease (CD) who 
had received immunosuppressive treatment in addition to 
natalizumab (Van Assche et al 2005). Natalizumab may allow 
the development of PML by reducing the transmigration of 
lymphocytes into the CNS and thus prevent or attenuate CNS 
immunosurveillance, however other immune mechanisms may 
be involved (Niino et al 2006). Natalizumab was withdrawn 
from the market in February 2005 and ongoing studies were 
suspended; patients who had received natalizumab were invited 
to participate in screening for other cases of PML. Based on 
this patient population, who received a mean of approximately 
18 monthly doses of natalizumab, it was estimated that the 
incidence of PML was 1 case per 1000 patients over 18 months 
(95% CI 0.2–2.8) (Yousry et al 2006).
Immunogenicity
An immune response to protein therapeutic agents will lead 
to the development of neutralizing antibodies in a proportion 
Table 3 Phase 3 studies of natalizumab: 2-year results
 Natalizumab  Placebo  P-
  (n = 627)  (n = 315)  Value
AFFIRM (Polman et al 2006)
Clinical endpoints
Annualized relapse rate, mean (95% CI)  0.23 (0.19, 0.28)  0.73 (0.62, 0.87)  <0.001
Sustained disability progressiona, % of patients  17  29  <0.001
MRI endpoints (lesions per patient)
No. of new or enlarging T2 lesions, mean ± SD  1.9 ± 9.2  11.0 ± 15.7  <0.001
No. of Gd+ lesions, mean ± SD  0.1 ± 1.4  1.2 ± 3.9  <0.001
  Natalizumab +   Placebo +   P-
 IFNβ-1a (n = 589)  IFNβ-1a (n = 582)  Value
SENTINEL (Rudick, Stuart, et al 2006)
Clinical endpoints
Annualized relapse rate, mean (95% CI)  0.34 (0.29, 0.39)  0.75 (0.67, 0.84)  <0.001
Sustained disability progression, % of patients  23  29  0.02
MRI endpoints (lesions per patient)
No. of new or enlarging T2 lesions, mean ± SD  0.9 ± 2.1  5.4 ± 8.7  <0.001
No. of Gd+ lesions, mean ± SD  0.1 ± 0.6  0.9 ± 3.2  <0.001
Note: aDeﬁ  ned as either a ≥1.0-point increase in EDSS from a baseline of ≥1.0, or a ≥1.5-point increase in EDSS from a baseline of 0. The change was required to be 
sustained for at least 12 weeks and could not be conﬁ  rmed during a relapse.
Abbreviations: CI, conﬁ  dence interval; Gd+, gadolinium enhancing; IFN, interferon; MRI, magnetic resonance imaging; SD, standard deviation.Therapeutics and Clinical Risk Management 2007:3(2) 266
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of patients; most natalizumab clinical studies assessed 
patients for the presence of natalizumab-reactive antibodies 
in serum (Sheremata et al 1999; Miller et al 2003; Vollmer 
et al 2004; Polman et al 2006; Rudick, Stuart, et al 2006). 
In the AFFIRM and SENTINEL Phase 3 studies, 6% of 
patients developed persistent antinatalizumab antibodies, 
which were associated with an increase in infusion-related 
AEs and a decrease in the efﬁ  cacy of natalizumab (Polman 
et al 2006; Rudick, Stuart, et al 2006). In the AFFIRM study, 
antibodies were detected in 57 of 625 (9%) of natalizumab-
treated patients: 20 (3%) were transiently positive and 37 
(6%) were persistently positive. Persistently positive patients 
showed a loss of clinical efﬁ  cacy as measured by disability 
progression (p ≤ 0.05), relapse rate (p = 0.009), and MRI 
(p ≤ 0.05) compared with antibody-negative patients. In 
transiently positive patients, full efﬁ  cacy was achieved 
after approximately 6 months of treatment, the time when 
patients were becoming antibody negative. The incidence of 
infusion-related adverse events was signiﬁ  cantly higher in 
persistently positive patients. Results of SENTINEL were 
similar to AFFIRM, except with regard to sustained disability 
progression (Calabresi et al 2007). 
Clinical indications and patient 
support/disease management 
programs
Natalizumab is now approved for treatment of MS in both 
North America and the EU. In the EU, natalizumab is indicated 
as monotherapy for patients with relapsing-remitting MS 
who have high disease activity despite treatment with IFNβ, 
and for patients with rapidly evolving severe relapsing-
remitting MS. In the former case, patients should have had 
at least one relapse in the previous year while on therapy and 
have ≥9 T2 lesions or ≥1 Gd+ lesion on cranial MRI; in the 
latter case, patients should have had two or more disabling 
relapses in one year and ≥1 Gd+ lesion or an increase T2 
lesion load relative to another recent cranial MRI scan. In 
the US, natalizumab is indicated as monotherapy for patients 
with relapsing forms of MS; it is generally recommended 
for patients who have had an inadequate response to, or are 
unable to tolerate, alternate MS therapies.
The relative beneﬁ  ts and risks of natalizumab therapy for 
a particular patient will depend on disease severity, treatment 
history, and factors that could cause immunocompromise. 
Risk minimization is achieved by promoting informed 
beneﬁ  t–risk decisions, ensuring that natalizumab is not 
prescribed to immunocompromised patients, and maintaining 
vigilance for PML and other adverse events. In the EU, 
prescribing will be limited to physicians experienced in the 
treatment of neurological diseases and with timely access 
to MRI, in facilities that are prepared to deal with any 
hypersensitivity reactions. Education directed to physicians 
will cover guidance on the appropriate patient population for 
treatment, algorithms for managing suspected cases of PML, 
and information on other risks. 
Upon reintroduction of natalizumab for clinical use in 
the US, Biogen Idec implemented a comprehensive risk 
management plan, which is called Tysabri Outreach: Uniﬁ  ed 
Commitment to Health (TOUCH). The purpose of TOUCH 
is to minimize known risks to patients and to continually 
reassess risks based on new data. Natalizumab will be made 
available in North America only to healthcare professionals 
and patients who meet requirements for inclusion in the 
TOUCH program. These requirements were chosen to ensure 
that prescribers and patients understand the risks of treatment 
with natalizumab, including PML and other opportunistic 
infections, and take advantage of several unique features of 
natalizumab distribution and administration. The enrolled 
prescriber counsels the patient on the risks and beneﬁ  ts of 
natalizumab therapy before an initial prescription is written. 
Administration of natalizumab is restricted to infusion centers 
where the staff has been educated about risks and appropriate 
use. During monthly infusion visits, members of the medical 
staff have regular opportunities to inform patients about PML 
risk and to screen for early symptoms of PML. Prescribing 
guidelines also state than an MRI scan should be obtained 
prior to treatment to help differentiate future MS symptoms 
from PML. Patient and physician data, after signed approval, 
are entered into a database maintained by Biogen Idec. The 
inclusion of all healthcare providers and patients in TOUCH 
will provide data for further deﬁ  ning the safety proﬁ  le of 
natalizumab.
In addition, the safety of natalizumab is being further 
assessed in a 5000-patient registry cohort (the Tysabri Global 
Observation Program in Safety [TYGRIS] study) in the EU 
and North America, with 5-year follow-up for infections 
requiring hospitalization, cases of PML, malignancies, 
and all adverse events which are serious or medically 
signiﬁ  cant. This study has an estimated 95% probability of 
detecting adverse events that occur at a frequency of at least 
1 in 1500 patients. A comprehensive series of additional 
epidemiological, clinical, and nonclinical studies are either 
in progress or planned, including a redosing study, a registry Therapeutics and Clinical Risk Management 2007:3(2) 267
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of approximately 300 pregnant patients, and examinations 
of immune function and vaccine response.
Support and information for patients with MS are also 
offered by national and international nonproﬁ  t, medical, and 
scientiﬁ  c organizations. These include the Multiple Sclerosis 
Association of America, the Multiple Sclerosis Foundation, 
the National Multiple Sclerosis Society, the Consortium 
of Multiple Sclerosis Centers, the International Multiple 
Sclerosis Support Foundation, and the Multiple Sclerosis 
International Federation.
Conclusions
Natalizumab fills an unmet medical need because of 
it provides a new level of efficacy in slowing disease 
progression and reducing relapses in MS patients. In 
addition, patient acceptance should be positively impacted 
by the convenience of dosing and long-term tolerability. 
These characteristics make natalizumab an important new 
therapeutic option for patients with relapsing MS. The 
efﬁ  cacy and safety of natalizumab are supported by evidence 
from multiple, randomized, controlled clinical trials (Miller 
et al 2003; Polman et al 2006; Rudick, Stuart, et al 2006). 
A rapid and sustained treatment effect was observed in a 
large Phase 2 trial in patients with relapsing MS, in which 
natalizumab reduced relapses by 50% and the formation of 
Gd+ MRI lesions by approximately 90%, compared with 
placebo (Miller et al 2003). The large, controlled, Phase 3 
trials (the AFFIRM and SENTINEL studies), which led to 
approval of natalizumab in the EU and US, are among the 
most rigorous and well-designed trials of DMTs to date, 
and are the most relevant indicators of likely performance 
in the general population of patients with relapsing MS. 
After 2 years in the AFFIRM study, patients treated with 
natalizumab monotherapy had an annualized relapse rate 
68% lower than that of patients receiving placebo (Polman 
et al 2006); this is approximately double the reduction 
typically observed with IFNs or GA (IFNB 1993; Johnson 
et al 1995; Jacobs et al 1996; PRISMS 1998). In the same 
study, sustained disability progression was decreased by 
42%, and the mean number of new brain lesions was reduced 
by 83 to 92% (Polman et al 2006). In the SENTINEL study 
of patients with continued disease activity despite receiving 
IFNβ-1a therapy, the addition of natalizumab to the standard 
regimen of IFNβ-1a decreased the annualized relapse rate 
by 55%, sustained disability progression by 24%, and the 
mean number of new lesions by 83 to 89%, compared with 
IFNβ-1a alone (Rudick, Stuart, et al 2006). Uniquely, among 
the trials of DMTs, signiﬁ  cant efﬁ  cacy was seen in nearly 
all primary, secondary, and tertiary endpoints, including the 
quality of life measurements. Although direct head-to-head 
comparisons have not been performed, the preponderance 
of data strongly supports the notion that natalizumab offers 
greater efﬁ  cacy than existing DMTs. Clearly, since MS is a 
life-long illness, it is important to recognize that the beneﬁ  ts 
found on relatively short-term measures seen in clinical trials 
may not translate into long-term effects in the prevention of 
disability progression. Natalizumab is not a cure for RRMS 
but it is a signiﬁ  cant improvement on current therapy and 
given its efﬁ  cacy and tolerability, natalizumab fulﬁ  lls an 
unmet medical need in the treatment of MS. 
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